Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer
This study has been terminated.
Study NCT00051584 Information provided by Seattle Genetics, Inc.
First Received: January 13, 2003 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
Gemzar (Gemcitabine)
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Doxorubicin
Gemcitabine
Immunoconjugates
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Seattle Genetics, Inc.
Back to top of Main Content
